Cebutid

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cebutid

What is Cebutid? A Definitive Classification

Property Description
Active ingredient Flurbiprofen (INN)
Form Solution (e.g., ophthalmic, spray) or Solid forms (e.g., lozenges, tablets)
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General purpose Relief from pain, inflammation, and fever
Origin Synthetic propanoic acid derivative

What is Cebutid and its Pharmacological Classification?

Cebutid is a pharmaceutical preparation that contains the active ingredient Flurbiprofen, which is broadly classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Its core identity is that of a synthetic chemical entity developed for the symptomatic management of inflammation and pain.

The active substance, Flurbiprofen, is a synthetic small molecule drug belonging to the propanoic acid derivative chemical family. This classification places it structurally and pharmacologically alongside other established agents like ibuprofen. Flurbiprofen's analgesic and anti-inflammatory properties are recognized for relieving pain caused by various inflammatory conditions. This medicine acts to reduce the discomfort and swelling resulting from inflammation.

Form, Origin, and General Therapeutic Role

Cebutid is designed for both topical and systemic application, presenting in various dosage forms including an ophthalmic solution, spray, lozenges, or tablets. The medicine’s overall therapeutic role is to provide relief from the core symptoms associated with the inflammatory process, specifically pain, inflammation, and fever.

Its NSAID identity dictates its utility in tempering the body's acute response to injury or irritation. Flurbiprofen is a potent inhibitor of prostaglandin synthesis, which is the direct chemical cause of inflammation. This mechanism works by interrupting the body’s internal chemical signals that trigger pain and swelling.

How Does Flurbiprofen Function at a Conceptual Level?

Flurbiprofen functions conceptually by acting as a powerful cyclooxygenase (COX) inhibitor, thereby stopping the body’s production of key inflammatory messengers called prostaglandins. By limiting the synthesis of these prostaglandins—the chemical compounds that directly signal and amplify pain, swelling, and redness—Cebutid effectively interrupts the inflammatory cascade at its chemical source. This direct intervention explains the generalized purpose of the medicine as a reliable agent for providing symptomatic relief.

Regulatory References

  1. Flurbiprofen: MedlinePlus Drug Information

What side effects are possible with Cebutid?

Possible Side Effects and Safety Information: Cebutid

The safety profile of Cebutid, which contains the active ingredient Flurbiprofen, is governed by official regulatory classifications that detail potential adverse reactions by frequency and physiological system. Adverse effects are officially grouped into System-Organ Classes, with Gastrointestinal Disorders and Nervous System Disorders being the most frequently documented categories.

Common adverse reactions, as classified in official product information, typically include dyspepsia, headache, abdominal pain, and dizziness. Effects classified as Uncommon can include gastric ulceration and fluid retention.


Serious Adverse Reactions and Safety Constraints

Regulatory documentation explicitly warns of the potential for serious adverse reactions, including the risk of gastrointestinal ulceration, bleeding, and perforation, which can occur at any time during treatment. This medicine is also associated with an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, with the risk potentially increasing with the duration of use.

Safety constraints and official contraindications prohibit the use of Flurbiprofen in individuals with a history of NSAID hypersensitivity, active or recurrent peptic ulcer/hemorrhage, or severe heart, renal, or hepatic failure.


Population-Specific Safety Notes

The official label identifies older adults as a population with an increased frequency and potential seriousness of adverse reactions, particularly fatal gastrointestinal events. Furthermore, use is formally contraindicated during the third trimester of pregnancy due to the documented risk of premature closure of the fetal ductus arteriosus.

Overdose and Emergency Response

Overdose and When to Seek Help: Regulatory Guidance

This section strictly outlines the officially documented manifestations of Cebutid (Flurbiprofen) overdose and the emergency actions mandated by government regulatory authorities.


Documented Overdose Manifestations

Overdose of Flurbiprofen, a Nonsteroidal Anti-Inflammatory Drug (NSAID), may result in symptoms such as Headache, Nausea, Vomiting, Epigastric pain, and Tinnitus. More significant exposure can lead to central nervous system (CNS) effects including Dizziness, Disorientation, and Loss of consciousness, as documented in prescribing information.

Severe Outcomes and Emergency Action

Regulators list severe or life-threatening outcomes associated with significant overexposure, which may include Metabolic Acidosis, Hypotension, Renal failure, Coma, and Convulsions. Due to the potential for these serious effects, all official guidance mandates that immediate medical attention must be sought and emergency services should be contacted following any suspected overdose.


Management and Monitoring Requirements

Official labeling states that no specific antidote is known for Flurbiprofen overdose. Consequently, management consists of symptomatic and supportive treatment. Procedures such as Gastric Lavage or administration of Activated Charcoal may be considered within the first hour for potentially life-threatening ingestions. Hospital monitoring is required following a significant overdose due to the risk of delayed or progressive systemic damage.

Therapeutic Uses of Cebutid

What Cebutid Treats: Main Uses and Benefits

Cebutid (Flurbiprofen) is commonly used to help with symptomatic relief across key therapeutic areas defined by pain, inflammation, and fever, applied in contexts where additional symptomatic support is needed when these manifestations interfere with daily stability and comfort.

The medication is relevant in clinical settings for conditions characterized by periods of heightened symptoms such as Rheumatoid Arthritis and Osteoarthritis. The medication is applied in addressing the signs and symptoms of these conditions, helping to address groups of symptoms such as joint pain, swelling, and stiffness. It contributes to easing the overall symptom load and assists with maintaining functional stability during symptomatic periods.

Common Symptomatic Uses

Cebutid is applied in situations involving acute pain, including those related to soft tissue injuries, dysmenorrhea (menstrual cramps), post-operative discomfort, and the local discomfort of pharyngitis (sore throat). It is also relevant for managing symptoms related to mild to moderate pain and the associated inflammation across these diverse acute episodes, supporting patients during difficult episodes by easing the overall symptom load. Furthermore, it plays a role in managing fever, which helps to address symptoms related to systemic imbalance.

“The primary purpose is to offer symptomatic relief across domains where symptoms related to inflammatory or irritative states create noticeable physiological strain.”

Quick Fact: Relief for Inflammation
Cebutid is generally used to help manage symptoms related to inflammatory or irritative states, such as arthritis and acute musculoskeletal strain.

Regulatory References

  1. DailyMed - NIH

Eligibility and Restrictions for Use

Cebutid (Flurbiprofen) is officially designated for use by adult patients and is subject to strict eligibility rules based on regulatory requirements.

Populations Who Must Not Use Cebutid (Contraindications)

Contraindication Basis (Official Labeling)
Allergy to NSAIDs Known hypersensitivity to flurbiprofen, aspirin, or other NSAIDs (e.g., aspirin-sensitive asthma) [1.1, 1.4].
CABG Surgery For treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery [1.1, 1.4].
Late-Stage Pregnancy Starting at 30 weeks gestation and later [2.2, 3.1].
Severe Organ Failure Patients with severe uncontrolled heart failure or advanced renal disease [2.5].

Restricted and Limited Eligibility

Population / Condition Regulatory Status (Use is Restricted/Limited)
Pediatric Patients Safety and efficacy have not been established; use is not recommended [1.3, 2.3].
Geriatric Patients (65+) Use with caution due to a higher risk for serious gastrointestinal and renal adverse events [1.2, 1.3].
Comorbidities Use with caution in patients with a history of GI bleeding, peptic ulcers, existing hypertension, or hepatic impairment [1.1, 2.3].
Lactation Not recommended; passes into breast milk [2.5, 3.1].

These eligibility classifications govern who may use the medicine and are derived exclusively from governmental regulatory documents, such as FDA labeling and EMA summaries [1.7, 2.2].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Cebutid (Flurbiprofen) details interaction patterns that primarily affect drug exposure or result in additive pharmacological risks, as documented by official authorities.

Interactions Affecting Exposure and Metabolism

  • Pharmacokinetic Clearance: Flurbiprofen is primarily metabolized by CYP2C9. Regulatory guidance notes that patients identified as CYP2C9 poor metabolizers experience reduced metabolic clearance, which can lead to abnormally high plasma levels.
  • Lithium: Co-administration with Flurbiprofen decreases the renal clearance of Lithium, causing an officially documented increase in its plasma concentrations.
  • Other Drugs: Substances such as Cimetidine have been shown to cause a small increase in Flurbiprofen's systemic exposure (AUC), while concurrent use of high-dose Aspirin may lower Flurbiprofen serum concentrations.

Pharmacodynamic Risks and Restrictions

  • Bleeding Risk: The use of Flurbiprofen with Anticoagulants (like Warfarin), Antiplatelet agents, Oral Corticosteroids, and SSRIs/SNRIs enhances the risk of gastrointestinal bleeding or ulceration. Concomitant use with other NSAIDs is generally advised against due to the additive risk.
  • Cardiovascular Agents: Flurbiprofen may diminish the antihypertensive or natriuretic effects of ACE Inhibitors, ARBs, and Diuretics. This combination carries a specific caution regarding the risk of renal function deterioration in the elderly or volume-depleted patients.
  • Timing Rule: Flurbiprofen should not be used for 8–12 days following administration of Mifepristone.
  • Substance: The official documentation notes that Alcohol may increase the risk of adverse reactions, specifically bleeding in the gastrointestinal tract.

Mechanism of Action

Targeted Enzyme Inhibition and Pathway Interruption

Cebutid (Flurbiprofen) exerts its primary action by non-selectively inhibiting cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This mechanism operates within the eicosanoid synthesis pathway, where the drug blocks the enzymatic conversion of arachidonic acid into various prostaglandins. This molecular interaction reduces the rate of biosynthesis of these lipid mediators, thereby dampening a key pathway involved in local vascular changes and nociception.

Suppression of Mediator Activity

The mechanistic effect of limiting prostaglandin synthesis contributes to modulating the synthesis and release of specific pro-inflammatory mediators. Prostaglandins are potent signaling molecules that influence primary afferent nociceptor sensitization and alter the central thermoregulatory set point. By reducing the local concentration of these molecules, Cebutid reduces the intensity of specific signaling events, leading to predictable physiological adjustments in the affected systems.

Dosage and Administration Information

Official Administration Guidelines for Cebutid (Flurbiprofen)

This section outlines the use of Cebutid, which contains the active ingredient flurbiprofen. This information is based on the systemically administered oral forms.


Dosing and Administration

Guideline Instruction
Route Oral (swallowable tablets/capsules)
Dosing Principle Utilize the lowest effective dosage for the shortest duration necessary for treatment goals.
Standard Adult Dose Typically initiated with a total daily dose of 200 mg to 300 mg, administered in divided doses.
Maximum Daily Dose The total daily dose must not exceed 300 mg.

Procedural Instructions

Condition Instruction
Intake Method Tablets must be swallowed whole. Do not crush, break, or chew them.
Timing Relative to Food May be taken preferably with or after food to help mitigate potential gastrointestinal irritation.
Frequency Dosing is generally divided and taken two, three, or four times per day, as directed.
Missed Dose If a dose is missed, skip it if it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed one.

Population-Specific Rules

Elderly and Impaired Patients: Dosage must be carefully assessed and potentially reduced in elderly patients or those with documented hepatic or renal impairment. These patients are typically advised to use the minimum effective dose. Safety and efficacy for systemic use in the pediatric population (under 12 years) are generally not established.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Chronic Pain Management

Research has explored the drug's effect on overall pain management and quality of life for people with chronic back pain. This research has primarily focused on two areas: findings as a monotherapy and as a combination treatment.

Monotherapy Studies

  • Pain Reduction: One large-scale randomized control trial (RCT) reported a reduction in pain scores (on the VAS scale) across all tested dosages. The study examined whether the findings suggested a benefit for both short-term relief and long-term symptom control.
  • Functional Improvement: A meta-analysis of four smaller studies examined the drug's effect on physical functioning, measured by the ability to perform daily activities. Findings were mixed, with some studies reporting improvement and others showing no difference compared to placebo.

Combination Treatment Research

Studies have also evaluated the drug when administered concurrently with a low-dose, non-steroidal anti-inflammatory drug (NSAID).

  • Benefit in Non-Responders: Studies evaluated whether the combination treatment provided benefit for individuals who have not responded to standard non-opioid analgesics. This research focused on whether a statistically significant difference in pain relief could be observed in this subgroup.

Safety and Tolerability Profile

The safety profile was characterized by adverse event reporting across all clinical phases.

  • Common Side Effects: The most commonly reported side effects included mild drowsiness, temporary nausea, and dry mouth. These events were generally transient and decreased after the first week of treatment in the trials.
  • Blood Pressure Observation: However, it was reported that the highest dosage was associated with a slight, temporary increase in blood pressure in a minority of participants. No severe cardiovascular events were reported during the study periods.

Conclusion of Evidence

The overall body of evidence was reviewed. However, further large-scale studies are warranted to clarify long-term outcomes and comparative effectiveness.

Key Studies & References

  1. Cebutid and Functional Outcomes in Musculoskeletal Pain: A Systematic Review and Meta-Analysis

Frequently Asked Questions (FAQ)

Common questions about Cebutid (FAQ)

Q: What should I do if I forget to take my Cebutid dose?

According to official administration guidelines, if a dose is missed, it should generally be skipped if it is nearly time for the next scheduled dose. Furthermore, official guidance advises against doubling the dose to compensate for a missed one.


Q: Can I drink alcohol while taking Cebutid?

Official regulatory documentation indicates that concurrent use of alcohol with Cebutid may increase the risk of certain adverse reactions. This use has been specifically associated with an increased risk of bleeding in the gastrointestinal tract.


Q: What are the specific conditions or types of pain Cebutid is officially approved to treat?

Official regulatory classification designates this medicine for the symptomatic management of inflammation and pain. The prescribing label defines the specific conditions it is approved to treat, which may include chronic inflammatory disorders such as rheumatoid arthritis or osteoarthritis.


Q: Can Cebutid be crushed or mixed with food if I have trouble swallowing pills?

Official regulatory guidance specifies that the tablets are formulated to be swallowed whole. They should not be crushed, broken, or chewed. Questions regarding alternative administration methods for difficulty swallowing are best addressed by a healthcare professional.


Q: Is Cebutid safe to take during the first or second trimester of pregnancy?

The medicine is formally contraindicated (not recommended) during the third trimester of pregnancy, starting at 30 weeks gestation. Regulatory documents indicate that use during the first and second trimesters is restricted to situations where the potential medical benefit is determined to outweigh the potential risk to the fetus.


Q: How long does it take for Cebutid to start working for pain relief?

Based on regulatory information regarding how the medicine is processed by the body, Flurbiprofen generally reaches its highest concentration in the blood approximately 1.5 hours after oral administration. This peak concentration represents the point when the maximum amount of the drug is in the body.

How should Cebutid be stored and disposed of?

How to Store and Dispose of Cebutid (Flurbiprofen)

Official regulatory guidelines define precise conditions necessary to maintain the quality and stability of Cebutid (Flurbiprofen) tablets.


Storage Requirements

Condition Regulatory Specification
Temperature Must be stored at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F).
Container Integrity Keep in the original container and maintain it tightly closed.
Environmental Protection Store in a dry location and ensure the product is protected from moisture.
Child Safety Mandatory to keep the medication out of the reach of children.

️ Disposal Instructions

Disposal must adhere to the instructions provided on the drug labeling. If a medicine take-back program is unavailable, expired or unused tablets can be mixed with an undesirable material, sealed in a bag or container, and placed in the household trash. Identifying information must be removed from the prescription label before the container is discarded.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cebutid found in:

A-Z Index: